Angion Biomedica Corp. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
$ANGN
Biotechnology: Pharmaceutical Preparations
Health Care
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date of Report (date of earliest event reported): January 9, 2024
(Exact name of registrant as specified in its charter)
|
|
|
|
|
(State or other jurisdiction of incorporation or organization)
|
(Commission File Number)
|
(IRS Employer Identification No.)
|
(Address of principal executive offices, including zip code )
(857 ) 209-0050
Registrant’s telephone number, including area code
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following
provisions (see General Instruction A.2. below):
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
|
(Title of each class)
|
(Trading Symbol)
|
(Name of exchange on which registered)
|
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule
12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised
financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
| Item 8.01 |
Other Events.
|
On January 9, 2024, Elicio Therapeutics, Inc. (the “Company”) issued a press release announcing
the publication of updated preliminary data from the Company’s ongoing Phase 1 (AMPLIFY-201) solid tumor study of its lead asset, ELI-002, in Nature Medicine. A copy of the
press release is attached as Exhibit 99.1 to this Current Report and is incorporated herein by reference. Attached as Exhibit 99.2 and incorporated herein by reference is an updated
version of the Company’s corporate presentation, which was uploaded to the Company’s website on January 9, 2024.
| Item 9.01. |
Financial Statements and Exhibits.
|
| (d) |
Exhibits.
|
|
Exhibit
Number
|
Exhibit
Description
|
|
|
Press Release of Elicio Therapeutics, Inc., dated January 9, 2024
|
||
|
Corporate presentation dated January 9, 2024
|
||
|
104
|
Cover Page Interactive Data File (embedded within the Inline XBRL document)
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its
behalf by the undersigned hereunto duly authorized.
|
Elicio Therapeutics, Inc.
|
||
|
By:
|
/s/ ROBERT CONNELLY
|
|
|
Robert Connelly
President and Chief Executive Officer
(Principal Executive Officer)
|
||
|
Date: January 9, 2024
|
||